Long-term treatment outcomes for methamphetamine dependence: A 3 year follow-up of the MATES cohort

NDARC Staff

Rebecca McKetin, Joanne Ross, Richard Mattick, Rachel Sutherland and Erin Kelly

Other Investigators

Jake Najman (QADREC, University of Queensland), Amanda Baker (University of Newcastle), Abdullah Mamun (University of Queensland).

Aims

The Methamphetamine Treatment Evaluation Study (MATES) is the first and only longitudinal treatment outcomes study for methamphetamine use in Australia. This internationally unique study is designed to assess whether existing drug treatment services are effective in reducing methamphetamine use and related problems (e.g., psychosis and depression). The first phase of the study found that methamphetamine users responded positively to drug treatment, with large reductions in drug use, related psychiatric morbidity, crime and HIV risk behavior. The aim of the MATES 3 year follow-up is to assess longer-term treatment outcomes for methamphetamine use.

Design and Method

MATES is a prospective longitudinal cohort study. Participants in the MATES cohort will be re-contacted and interviewed 3 years after their entry to drug treatment. The interview will assess methamphetamine use, other drug use, and major drug-related harms (e.g., HIV risk, crime, psychosis).

Progress

Ethics for the 3 year follow-up has been obtained and follow-up interviews are underway.

Funding

Australian Government Department of Health and Ageing ($138,600)

Participants

Participant Information Sheet